Clinical Trials
17 trialsNCT03798626 2026-04-01
Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers
Novartis
Phase 1 Completed
NCT05007106 2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT00627432 2025-02-18
Gemcitabine With Or Without Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Bladder Cancer
Institut du Cancer de Montpellier - Val d'Aurelle
Phase 2 Completed
NCT00104676 2025-02-06
Combination Chemotherapy in Treating Patients With Stage II or Stage III Germ Cell Tumors
UNICANCER
Phase 3 Completed
NCT02009449 2024-11-15
IVY
Eli Lilly and Company
Phase 1 Completed
NCT03451331 2024-05-16
Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer
Hoosier Cancer Research Network
Phase 2 Completed
NCT03159143 2017-08-11
Study of Docetaxel and Oxaliplatin in Metastatic Transitional Cell Cancer (TCC) of the Urothelial Tract
University of Pittsburgh
Phase 2 Completed
NCT00183820 2017-07-07
Study of Gemcitabine, Oxaliplatin, and Paclitaxel in Patients With Refractory Germ Cell Carcinoma
University of Southern California
Phase 2 Completed
NCT00957905 2017-03-10
Alvocidib and Oxaliplatin With or Without Fluorouracil and Leucovorin Calcium in Treating Patients With Relapsed or Refractory Germ Cell Tumors
National Cancer Institute (NCI)
Phase 2 Completed
NCT01183663 2016-06-03
Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00260611 2015-03-25
Study of Oxaliplatin and Taxotere in Prostate Cancer
University of Pittsburgh
Phase 2 Completed
NCT01338792 2014-03-10
Oxaliplatin and Pemetrexed Disodium in Treating Patients With Refractory Hormone-Resistant Prostate Cancer
University of Southern California
Phase 2 Completed
NCT00004203 2013-09-05
Oxaliplatin in Treating Patients With Metastatic Bladder Cancer
University of Chicago
Phase 2 Completed
NCT00091182 2013-06-05
Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment
National Cancer Institute (NCI)
Phase 2 Completed
NCT00101270 2013-06-05
Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas
National Cancer Institute (NCI)
Phase 1 Completed
NCT00186277 2011-03-30
Phase II Study of Oxaliplatin and Taxotere in Metastatic Bladder Cancer
Stanford University
Phase 2 Completed
NCT00001835 2008-03-04
Oxaliplatin in Cancer Patients With Impaired Kidney Function
National Institutes of Health Clinical Center (CC)
Phase 1 Completed